Detalhe da pesquisa
1.
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.
Circulation
; 144(22): 1750-1759, 2021 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34706555
2.
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
Circulation
; 144(23): 1845-1855, 2021 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34710343
3.
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.
Circulation
; 143(1): 33-44, 2021 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33148016
4.
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
N Engl J Med
; 380(1): 11-22, 2019 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30415628
5.
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.
Circulation
; 141(5): 367-375, 2020 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31707829
6.
Human CHD1 is required for early DNA-damage signaling and is uniquely regulated by its N terminus.
Nucleic Acids Res
; 46(8): 3891-3905, 2018 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29529298
7.
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial.
Eur Heart J
; 45(13): 1173-1176, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38252107
8.
Response by Bhatt et al to Letter Regarding Article, "REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States".
Circulation
; 141(21): e834-e835, 2020 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32453660
9.
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.
J Am Coll Cardiol
; 83(16): 1529-1539, 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38530686
10.
Gene recoding by synonymous mutations creates promiscuous intragenic transcription initiation in mycobacteria.
bioRxiv
; 2023 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36993691
11.
Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn.
Eur Heart J Open
; 3(6): oead114, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-38035037
12.
Gene recoding by synonymous mutations creates promiscuous intragenic transcription initiation in mycobacteria.
mBio
; 14(5): e0084123, 2023 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37787543
13.
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT.
J Am Heart Assoc
; 12(5): e026756, 2023 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36802845
14.
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.
J Am Coll Cardiol
; 79(17): 1660-1671, 2022 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35483753
15.
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.
J Am Heart Assoc
; 11(6): e022937, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35261279
16.
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
J Am Coll Cardiol
; 78(15): 1525-1537, 2021 10 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34620410
17.
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
J Am Coll Cardiol
; 73(22): 2791-2802, 2019 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30898607
18.
Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.
Clin Cardiol
; 40(3): 138-148, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28294373
19.
REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results.
Eur Heart J Cardiovasc Pharmacother
; 7(3): e61-e63, 2021 05 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33010162